The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 27, 2020

Filed:

Jun. 15, 2018
Applicant:

Nantbio, Inc., Culver City, CA (US);

Inventors:

Benjamin Schilling, Culver City, CA (US);

C. Anders Olson, Culver City, CA (US);

Philip T. Liu, Culver City, CA (US);

Shiho Tanaka, Culver City, CA (US);

Assignee:

NantBio, Inc., Culver City, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/68 (2017.01); A61P 35/00 (2006.01); C07K 16/24 (2006.01); A61K 39/395 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 47/6879 (2017.08); A61K 39/00 (2013.01); A61K 39/395 (2013.01); A61K 47/6801 (2017.08); A61K 47/6849 (2017.08); A61K 47/6851 (2017.08); A61P 35/00 (2018.01); C07K 16/244 (2013.01);
Abstract

Compositions, methods, and uses of recombinant B7-H4 protein or binding motifs to B7-H4 protein that can reduce the immune suppression effect of B7-H4 in relation to T cell activation, proliferation, and conversion. Preferably, the recombinant B7-H4 protein has a plurality of mutations in N-glycosylation residue to reduce its inhibitory effect to T cell activation and proliferation. The recombinant protein having binding motifs to B7-H4 protein preferably includes a binding motif to IgC domain and another binding motif to IgV domain such that the immune-suppressive effects by two Ig-like domains are concurrently reduced.


Find Patent Forward Citations

Loading…